You are in: Home Page > News and Press Releases Archive
 News and Press Releases Archive print
Year 2010
Grifols initiates clinical investigation of a new treatment protocol for Alzheimer’s disease 02.06.2010
Grifols agreement with Pharmalink to acquire the intellectual property for the treatment of Post-Polio Syndrome (PPS) 20.05.2010
Sales of plasma products have grown by 8.2% at constant currency, reaching 184.6 million euros inthe first quarter of 2010 and driving the group’s turnover 28.04.2010
Grifols’ net profit increased by 21.6% in 2009 to 148 MM euros 25.02.2010


Year 2009

Grifols obtains FDA approval for a new in filling area in its Albumin plant in LA 23.12.2009
Grifols and financial institutions unanimously agree the novation of the syndicated facility 16.12.2009
Grifols builds a new solutions factory in Murcia 09.12.2009
Grifols reports a 14.9% increase in revenue in the first nine months of 2009 to 689.6 MM euros 04.11.2009
Spanish minister of Industry, Tourism and Trade visits Grifols’ facilities in LA. 26.10.2009
Grifols to break ground on a new testing laboratory in San Marcos, Texas (US). 16.10.2009
Grifols completes its USD600 million corporate bond issue in the US 07.10.2009
Grifols publishes interim results of its clinical trial on Alzheimer’s disease 21.09.2009
Grifols’ net profit rose 31.4% in the first half of 2009 to 81.7 MM euros 29.07.2009
Health Robotics and Grifols sign a collaboration agreement 30.06.2009
Grifols promotes European research into liver cirrhosis 11.06.2009
The shares of Grifols will be traded in the United States through ADRs 28.05.2009
Cerus and Grifols Extend INTERCEPT Blood System Distribution to Italy 26.05.2009
Grifols holds its Annual General Meeting 15.05.2009
Grifols’ net profit rose 33.8 % in the first quarter of 2009 to 41.6 million euros 28.04.2009
Grifols acquires control over a Swiss and Australian group through a €25 million investment 03.03.2009
Grifols’ net profit advanced 38.7% in 2008 to 121.7 million euros. 26.02.2009
Grifols Academy of Plasmapheresis opens in US 28.01.2009
Grifols gets a minority stake in Cardio3 BioSciences 19.01.2009


Year 2008

Dr. Anna Veiga joins the Board of Directors of Grifols as independent director 11.12.2008
Grifols boosts nine-month net profit by 43% to 92.8 million euros 30.10.2008
Flebogamma® DIF receives licensing in Australia 14.10.2008
Grifols' net profit rose 36.8% in the first half of 2008 to 62.2 million euros 27.08.2008
Grifols obtains USD 10.7 million loan to fund the purchase of 4 plasma centres in the United States 29.07.2008
Grifols holds its Ordinary General Meeting of Shareholders 13.06.2008
Grifols signs an agreement with Gambro Renal Products (GRP) for MARS® in Spain and Portugal 10.06.2008
Grifols obtains syndicated financing for 350 million euros 26.05.2008
Grifols’ net profit rose 33% in the first quarter of 2008 to 31.1 million euros 14.05.2008
Grifols obtains FDA licence for new filling area at its plasma products plant in the USA 07.05.2008
Cardinal Health and Grifols concluded an exclusive 6 year distribution agreement 23.04.2008
Grifols signs a new distribution agreement with CDEX for Spain, Portugal and Italy 15.04.2008
Grifols signs agreement with Stough Development Corporation to open 10 new plasma collection Centers in the United States 12.03.2008
Net profits for Grifols increased 93.4% in 2007 to reach 87.8 million euros 28.02.2008
Grifols acquires Novartis' former industrial complex 0f 31,000 square meters in Parets del Valles, Barcelona 17.01.2008

Year 2007
The TAC incorporates Grifols into the Ibex-35 11.12.2007
Grifols successfully concludes the transition to its new intravenous immunoglobulin, Flebogamma DIF® in the United States 22.11.2007
Grifols increased its business turnover by 8.7% in the first nine months of thr year to 524.5 million euros 08.11.2007
Grifols to announce Capital Investment Plan for €400 million over the next five years 29.10.2007
Grifols and Laboratorios Divasa sign a strategic cooperation agreement 22.10.2007
Grifols increases its income by 11.4% to 358 million euros in the first six months of the year 29.08.2007
Grifols obtains EMEA authorization for sale of new generation IVIG in Europe 27.08.2007
Grifols S.A. and Cerus Corporation agree to commercialize the INTERCEPT Blood System in Spain and Portugal 23.07.2007
Grifols holds its Ordinary General Meeting of Shareholders 20.06.2007
Grifols’ turnover reaches 182 million euros in the first quarter of 2007 10.05.2007
Grifols will manage 4 new plasma centers in the United States 04.05.2007
Grifols looks into acquiring Diesse, an Italian company specialized in in vitro diagnostics 18.04.2007
Grifols R&D is qualified as excellent in the Profarma Plan 2006 meeting 22.03.2007
Grifols announces expansion of US manufacturing capacity 14.03.2007
Grifols reports a 23.8 increase in sales in 2006 26.02.2007

Year 2006
Grifols licensed by the FDA to market a new generation of IGIV in the United States 27.12.2006
Grifols reports a 23.7% increase in sales in the first nine months of 2006 06.11.2006
Grifols launches PatientCare Program to address insurance lapses for hemophilia community 12.10.2006
Grifols' Diagnostic division launches new in vitro diagnosis line 25.07.2006
Grifols signs an agreement with Kardex Remstar for Latin America 19.06.2006
Grifols sets offer price at €4.4 per share. The offering is 10 times oversubscribed. 16.05.2006
Grifols holds its General Shareholders Meeting 04.04.2006
Grifols closes out 2005 with a 15% increase in turnover 03.2006
Grifols acquires 15 additional plasma collection centers through acquisition of PlasmaCare 03.2006

 

 back